In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
ABX464 in Phase 2a Trials for RA
Research is examining the safety and tolerability of two different doses of ABX464 in patients with moderate to severe active RA…
Tocilizumab Fails to Help COVID-19 Patients in Italian Study
(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease…
Ustekinumab for Behçet’s Disease? The Study Results Are In
In a multicenter, prospective, open-label study, ustekinumab therapy was effective in treating oral ulcers resistant to colchicine in patients with Behçet’s disease, according to study author David Saadoun, MD, PhD, Department of Internal Medicine and Clinical Immunology, Sorbonne University, Paris, and fellow researchers.1 Researchers focused on the topic because oral ulcers are often disabling, have…
Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology
As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…
FDA Approves Celecoxib in an Oral Solution
The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…
Influential Lancet Article on HCQ Retracted
NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…
2 Pediatric Indications Sought for Golimumab
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…
Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 123
- Next Page »